In March 2022, Pfizer announced that it was recalling a popular blood pressure medication (Accuretic) after several lots of the drug were found to contain unsafe levels of a known carcinogen called nitrosamine.
At least for now, the recall appears to be related to isolated batches of the drug and Pfizer claims that it has no evidence of “adverse events” related to the contamination. There is still the possibility, however, that this could turn into a much wider problem and lead to a wave of product liability litigation.
In this post, we will review the details of the recall and assess the likelihood of any mass tort litigation (and we have a new 2023 update at the bottom).